Latest News & Features
Americas
The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/Fetherstonhaugh reports. 27 November 2014
Americas
The US Supreme Court has now heard arguments in the appeal of Teva v Sandoz from the US Court of Appeals for the Federal Circuit. This could fundamentally change how patent decisions are reviewed by the Federal Circuit and the deference given to district court rulings, says Felicia Boyd of Barnes & Thornburg. 27 November 2014
Big Pharma
At first glance, it might seem odd for a company to both divide blood plasma and fight the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP. 26 November 2014
Big Pharma
A new EU policy will require pharmaceutical companies to provide clinical trial data when seeking marketing approval for their drugs. But how will they ensure adequate IP protection while embracing the new culture of transparency? LSIPR reports. 25 November 2014
Biotechnology
Earlier this year, the Advocate General of
the CJEU opined that stem cells from parthenotes are patentable. Franz-Josef Zimmer and Markus Grammel examine the reasoning behind his opinion. 4 November 2014
Big Pharma
Depositing a microorganism in a country may be crucial for obtaining a method patent in that jurisdiction, but can come with its pitfalls, says Peter ten Haaft. 4 November 2014
Americas
Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi. 4 November 2014
Americas
Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry. 3 November 2014
Americas
AstraZeneca has had a tough few years, with a clutch of patent expiries one of the most serious of its problems. So where does it go from here? To find out, LSIPR spoke to the Anglo-Swedish pharmaceutical company’s vice president of business development about the role IP is playing in its plans for future success. 3 November 2014
Asia-Pacific
Brand owners may use a multitude of approaches to crack down effectively on fake drugs. Andy Leck and Ren Jun Lim discuss the challenges of anti-counterfeiting efforts in Singapore. 3 November 2014